Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Evaluation of Myobrace for Crossbite Correction in Mixed Dentition (Myo vs Frankel)

20 septembre 2026 mis à jour par: tharwa Ali Mokred AL-awadi, Sana'a University

Evaluation of the Myobrace Appliance in Correcting Crossbite During the Mixed Dentition Stage: A Randomized, Controlled Clinical Trial

This randomized controlled clinical trial will evaluate the effectiveness of the Myobrace appliance in correcting anterior and posterior crossbite in children aged 6 to 10 years during the mixed dentition stage. The study will compare the clinical effects of Myobrace with those of the Frankel III appliance. The study will assess changes in occlusion, skeletal and dentoalveolar relationships, and soft tissue characteristics before and after treatment. The study will also evaluate the effectiveness of the two treatment approaches in improving crossbite correction and related orthodontic outcomes.

Aperçu de l'étude

Description détaillée

Crossbite is a common malocclusion in children and may involve anterior or posterior teeth. Early management during the mixed dentition stage may help improve the occlusal relationship and reduce the potential for progression of the malocclusion.

This randomized controlled clinical trial is designed to evaluate the effectiveness of the Myobrace appliance for the correction of crossbite in children aged 6 to 10 years during the mixed dentition stage. The study will compare treatment with the Myobrace appliance with treatment using the Frankel III appliance.

Eligible children with anterior and/or posterior crossbite will be allocated to one of the treatment groups according to the study randomization protocol. Participants will receive the assigned appliance and will be followed throughout the treatment period according to the study protocol.

Treatment effectiveness will be evaluated by comparing clinical and orthodontic measurements obtained before and after treatment. The assessment will include correction of the crossbite and changes in skeletal, dentoalveolar, and soft tissue relationships. Cephalometric analysis will be used to assess relevant skeletal, dentoalveolar, and soft tissue changes.

The study will provide clinical information regarding the effectiveness of Myobrace treatment for crossbite correction during the mixed dentition stage and will allow comparison of its treatment effects with those of the Frankel III appliance.

Type d'étude

Interventionnel

Inscription (Réel)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Amanat Al Asimah
      • Sanaa, Amanat Al Asimah, Yémen
        • Faculty of Dentistry, Sana'a University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

6 ans à 10 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Clinical diagnosis of anterior crossbite, posterior crossbite, or both.
  • Yemeni children aged 6 to 10 years.
  • Children in the mixed dentition stage.
  • No history of prior orthodontic treatment.

Exclusion Criteria:

  • Children with craniofacial anomalies, such as cleft lip and palate.
  • Children with severe jaw misalignment requiring complex therapy.
  • Children with complete permanent dentition.
  • Children currently undergoing orthodontic treatment
  • Children or parents/guardians unwilling to provide informed consent or participate in the study.
  • Children with predicted or observed poor compliance, including behavioral issues that may interfere with treatment or study procedures.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Myobrace Group

Participants assigned to this arm will receive the Myobrace® Interceptive Class III appliance during the mixed dentition stage. Participants will be instructed to wear the appliance for approximately 1-2 hours during the day and overnight, together with daily myofunctional exercises and instructions regarding nasal breathing, tongue posture, swallowing, and lip competence. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first.

Participants will receive the Myobrace® Interceptive Class III appliance during the mixed dentition stage. The appliance will be used according to the study treatment protocol, with instructions for approximately 1-2 hours of daytime wear and overnight wear, together with daily myofunctional exercises and instructions regarding nasal breathing, tongue posture, swallowing, and lip competence. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first.

Comparateur actif: Frankel III Group

Participants assigned to this arm will receive the Frankel III (FR-III) functional regulator during the mixed dentition stage. The appliance will be used according to the clinical treatment protocol. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first. Clinical and cephalometric assessments will be performed before and after treatment to evaluate changes in skeletal, dentoalveolar, and occlusal relationships.

Participants will receive the Frankel III (FR-III) functional regulator during the mixed dentition stage. The appliance will be used according to the study treatment protocol. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first. Clinical and cephalometric assessments will be performed before and after treatment to evaluate changes in skeletal, dentoalveolar, and occlusal relationships.

Autres noms:
  • FR-III

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Crossbite Correction Status
Délai: Baseline, and up to 18 months

Change in occlusal crossbite status from baseline to treatment completion, assessed clinically by the presence or absence of anterior and/or posterior crossbite. Complete correction is defined as establishment of a normal anterior and/or posterior buccolingual occlusal relationship according to the type of crossbite present at baseline. The change will be assessed for each participant by comparing the post-treatment crossbite status with the participant's baseline status. The changes will then be compared between the Myobrace and Frankel III groups.

Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Overjet
Délai: Baseline, and up to 18 months.

Change from baseline in overjet, measured in millimeters (mm) as the horizontal distance between the maxillary and mandibular incisors. The change will be calculated for each participant by comparing the post-treatment overjet value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Overbite
Délai: Baseline, and up to 18 months.

Change from baseline in overbite, measured in millimeters (mm) as the vertical overlap between the maxillary and mandibular incisors. The change will be calculated for each participant by comparing the post-treatment overbite value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Anterior Crossbite Correction
Délai: Baseline, and up to 18 months.

Correction of anterior crossbite at treatment completion, assessed for each participant by comparing the post-treatment anterior crossbite status with the participant's baseline status. Correction is defined as establishment of a positive or normal horizontal overlap between the maxillary and mandibular anterior teeth that were in crossbite at baseline. The proportion of participants achieving anterior crossbite correction will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Posterior Crossbite Correction
Délai: Baseline, and up to 18 months.

Correction of posterior crossbite at treatment completion, assessed for each participant by comparing the post-treatment posterior crossbite status with the participant's baseline status. Correction is defined as establishment of a normal transverse buccolingual relationship between the maxillary and mandibular posterior teeth that were in crossbite at baseline. The proportion of participants achieving posterior crossbite correction will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in ANB
Délai: Baseline, and up to 18 months.

Change from baseline in the ANB angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment ANB value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SNA
Délai: Baseline, and up to 18 months.

Change from baseline in the SNA angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SNA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SNB
Délai: Baseline, and up to 18 months.

Change from baseline in the SNB angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SNB value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Wits Appraisal
Délai: Baseline, and up to 18 months.

Change from baseline in Wits appraisal, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Wits appraisal value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SN-MP
Délai: Baseline, and up to 18 months.

Change from baseline in the SN-MP angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SN-MP value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SN-OP
Délai: Baseline, and up to 18 months.

Change from baseline in the SN-OP angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SN-OP value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Ar-Go-Me (Gonial Angle)
Délai: Baseline, and up to 18 months.

Change from baseline in the Ar-Go-Me (gonial) angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Ar-Go-Me value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Y-axis (Por-Gns)
Délai: Baseline, and up to 18 months.

Change from baseline in the Y-axis (Por-Gns) angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Y-axis value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in FMA
Délai: Baseline, and up to 18 months.

Change from baseline in the FMA (Frankfort-Mandibular Plane Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment FMA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in IMPA
Délai: Baseline, and up to 18 months.

Change from baseline in the IMPA (Incisor to Mandibular Plane Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment IMPA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in FMIA
Délai: Baseline, and up to 18 months.

Change from baseline in the FMIA (Frankfort-Mandibular Incisor Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment FMIA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in S-Go Ratio
Délai: Baseline, and up to 18 months.

Change from baseline in the S-Go ratio, expressed as a percentage (%) on standardized lateral cephalometric radiographs. The ratio represents the posterior facial height (S-Go) relative to the anterior facial height (N-Me). The change will be calculated for each participant by comparing the post-treatment S-Go ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UI-SN
Délai: Baseline, and up to 18 months.

Change from baseline in the UI-SN angle (Upper Incisor to SN Plane), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment UI-SN value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Interincisal Angle (U1/L1)
Délai: Baseline, and up to 18 months.

Change from baseline in the interincisal angle (U1/L1), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment interincisal angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in U1/NA Angle
Délai: Baseline, and up to 18 months.

Change from baseline in the U1/NA angle (Upper Incisor to NA), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment U1/NA angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in U1/NA Linear Measurement
Délai: Baseline, and up to 18 months.

Change from baseline in the linear U1/NA measurement (Upper Incisor to NA), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment U1/NA linear measurement with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in L1/NB Angle
Délai: Baseline, and up to 18 months

Change from baseline in the L1/NB angle (Lower Incisor to NB), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment L1/NB angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months
Change in L1/NB Linear Measurement
Délai: Baseline, and up to 18 months.

Change from baseline in the linear L1/NB measurement (Lower Incisor to NB), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment L1/NB linear measurement with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Nasolabial Angle (Cotg-Sn-Ls)
Délai: Baseline, and up to 18 months.

Change from baseline in the nasolabial angle (Cotg-Sn-Ls), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment nasolabial angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Z Angle
Délai: Baseline, and up to 18 months.

Change from baseline in the Z angle (Merritt), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Z angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in N-Pog-H Line (H Angle)
Délai: Baseline, and up to 18 months.

Change from baseline in the N-Pog-H angle (H angle, Holdaway), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment N-Pog-H angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Ls-NsPog (U lip /E line)
Délai: Baseline, and up to 18 months

Change from baseline in the Ls-NsPog (upper lip to E-line) measurement, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Ls-NsPog value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months
Change in Li-NsPog (Lower Lip / E-Line)
Délai: Baseline, and up to 18 months.

Change from baseline in the Li-NsPog (lower lip to E-line) measurement, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Li-NsPog value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Sn-Stm : Stm-Me Ratio
Délai: Baseline, and up to 18 months.

Change from baseline in the Sn-Stm : Stm-Me ratio (Legan and Burstone), expressed as a percentage (%), representing the ratio of the upper lip height (Sn-Stm) to the lower lip and chin height (Stm-Me) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Gl-Sn-Pog (Facial Contour Angle)
Délai: Baseline, and up to 18 months.

Change from baseline in the Gl-Sn-Pog facial contour angle (Glabella-Subnasale-Pogonion), representing the soft tissue angle of facial convexity, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Gl-Sn-Pog angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UFH (Upper Facial Height)
Délai: Baseline, and up to 18 months.

Change from baseline in the upper facial height (UFH), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment UFH value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in LFH (Lower Facial Height)
Délai: Baseline, and up to 18 months.

Change from baseline in the lower facial height (LFH), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment LFH value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UFH: LFH ratio
Délai: Baseline, and up to 18 months.

Change from baseline in the UFH: LFH ratio (Upper Facial Height to Lower Facial Height), expressed as a percentage (%) on standardized lateral cephalometric radiographs. The ratio represents the upper facial height (UFH) relative to the lower facial height (LFH). The change will be calculated for each participant by comparing the post-treatment UFH:LFH ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Dr.Tharwa Alawadi, BDS, MSc, Sana'a University, Faculty of Dentistry
  • Chaise d'étude: Khaled AL-Haddad, Professor, Sana'a University, Faculty of Dentistry

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

23 avril 2025

Achèvement primaire (Estimé)

1 septembre 2027

Achèvement de l'étude (Estimé)

1 septembre 2027

Dates d'inscription aux études

Première soumission

14 septembre 2026

Première soumission répondant aux critères de contrôle qualité

20 septembre 2026

Première publication (Réel)

24 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • PE:01/09/2025

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be shared with other researchers. The study data will be used for the purposes of the current research and reported in aggregate form to protect participant confidentiality and privacy.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner